Cathay Biotech Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Cathay Biotech heeft een totaal eigen vermogen van CN¥15.0B en een totale schuld van CN¥1.3B, wat de schuld-eigenvermogensverhouding op 8.7% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥18.3B en CN¥3.3B. De EBIT Cathay Biotech is CN¥316.0M waardoor de rentedekking -2.4 is. Het heeft contanten en kortetermijnbeleggingen van CN¥4.6B.

Belangrijke informatie

8.7%

Verhouding schuld/eigen vermogen

CN¥1.30b

Schuld

Rente dekkingsratio	-2.4x
Contant	CN¥4.64b
Aandelen	CN¥14.99b
Totaal verplichtingen	CN¥3.34b
Totaal activa	CN¥18.33b

Recente financiële gezondheidsupdates

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Sep 29

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

May 28

Recent updates

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Oct 22

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Jun 19

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

May 28

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

May 07

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

May 06

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥6.8B ) 688065 } overtreffen de korte termijn passiva ( CN¥2.4B ).

Langlopende schulden: De kortetermijnactiva 688065 ( CN¥6.8B ) overtreffen de langetermijnschulden ( CN¥966.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 688065 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 688065 is de afgelopen 5 jaar gestegen van 6% naar 8.7%.

Schuldendekking: De schuld van 688065 wordt goed gedekt door de operationele kasstroom ( 55.1% ).

Rentedekking: 688065 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Cathay Biotech Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)

Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 23%

Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)

Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 21%

New major risk - Revenue and earnings growth

Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)

Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.

Price target increased by 8.3% to CN¥67.18

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)

Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023

Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group Limited

Full year 2022 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)

Less than half of directors are independent

Cathay Biotech Inc. announced that it has received $28 million in funding from Eight Roads Ventures, Sequoia China Investment Management LLP, Source Code Capital, Bits x Bites

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in 3Q 2021)

Price target increased to CN¥91.82

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.34 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥1.46 (vs CN¥1.18 in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.23 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.32 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.18 (vs CN¥1.32 in FY 2019)

Cathay Biotech Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥82.67

New 90-day low: CN¥88.56

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven